For UCSF Faculty and Staff: Please login via MyAccess to request access to update your Project.
Public Summary
The goal of this project is to develop engineered variants of the SARS CoV-2 Spike glycoprotein receptor binding domain (RBD) with decreased binding to the human receptor angiotensin converting enzyme 2 (ACE2). Our hypothesis is that decreasing binding of the RBD to ACE2 will increase the titer of antibodies that inhibit binding of the virus to the host receptor, known as neutralizing antibodies. Our previous studies with other microbial vaccine antigens have shown that this approach can increase the protective antibody responses by redirecting the antibody repertoire to better inhibit the interaction between the antigen and host protein.